Suggestions
Ljubomir Buturovic
VP Machine Learning at Inflammatix, Inc.
Ljubomir Buturovic is the Vice President of Machine Learning at Inflammatix, Inc., a company focused on developing diagnostic tests for infectious diseases.1 He has over 15 years of experience in developing and applying machine learning algorithms for clinical diagnostics.2
Dr. Buturovic holds a PhD in electrical engineering from the University of Belgrade, Serbia, and completed postdoctoral training at Boston University's BioMolecular Engineering Research Center.1 He has been an adjunct professor of computer science at San Francisco State University since 2005.1
At Inflammatix, Buturovic leads a team that leverages data science, machine learning, and artificial intelligence to develop robust clinical algorithms for the company's diagnostic tests.1 His work focuses on using machine learning to diagnose infections and sepsis, particularly in emergency room settings.4
Prior to joining Inflammatix, Buturovic was:
- Principal at Clinical Persona, a consulting firm specializing in machine learning for life sciences
- Chief scientist at Pathwork Diagnostics, where he led algorithm development for FDA-cleared genomics tests for cancer
- Bioinformatics director at Incyte Corporation1
Buturovic has published 70 manuscripts and is co-inventor on six issued US patents.2 His expertise spans bioinformatics, computational biology, and the application of machine learning in healthcare.3
Highlights
I wrote a commentary about Thrive AI Health, a new health venture announced by Sam Altman and Arianna Huffington.
Reality check regarding the AI/ML-based early cancer detection:
https://lnkd.in/ghQt_MsA
The great news is that NIH is launching a "Vanguard" study to evaluate the new technologies this year. But it'll take ~15 years to get the results (the two trials mentioned below will run in sequence):
"The Vanguard study is expected to take 4 years, according to Neslund-Dudas. The larger randomized controlled trial likely will have a 10-year to 12-year timeline."
Thus, it takes an extremely long time to determine if these innovations improve public health (as I explained in a prior article: https://lnkd.in/gjSzUrbM). This is a fundamental challenge for early cancer detection, independent of technology
Bottom line: whenever you read an article about new AI tech for cancer screening, think ~10-15 years to prove public health benefit (and remember the outcome could be negative)
